X4 Pharmaceuticals/$XFOR
1D1W1MYTD1Y5YMAX
Capital at risk
About X4 Pharmaceuticals
X4 Pharmaceuticals Inc is a biopharmaceutical company developing and commercializing novel therapeutics for the treatment of rare hematology diseases. The Company's clinical candidate is mavorixafor, a small molecule antagonist of the chemokine receptor CXCR4 that is being developed as an oral, once-daily therapy. It can increase the mobilization of mature, functional white blood cells from the bone marrow into the bloodstream. It also has two pre-clinical candidates X4P-003 and X4P-002 which are CXCR4 antagonists with different properties.
- Ticker
- $XFOR
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 45
- Headquarters
- Boston, United States
- Website
- www.x4pharma.com
XFOR Metrics
BasicAdvanced
$337M
-
-$0.89
0.39
-
Price and volume
Market cap
$337M
Beta
0.39
52-week high
$4.83
52-week low
$2.80
Average daily volume
758K
Financial strength
Current ratio
11.301
Quick ratio
10.845
Long term debt to equity
49.377
Total debt to equity
49.676
Interest coverage (TTM)
-9.23%
Profitability
EBITDA (TTM)
-79.004
Gross margin (TTM)
81.51%
Net profit margin (TTM)
-568.80%
Operating margin (TTM)
-509.06%
Effective tax rate (TTM)
0.03%
Revenue per employee (TTM)
$350,000
Management effectiveness
Return on assets (TTM)
-28.15%
Return on equity (TTM)
-113.08%
Valuation
Price to revenue (TTM)
21.864
Price to book
2.1
Price to tangible book (TTM)
2.61
Price to free cash flow (TTM)
-3.905
Free cash flow yield (TTM)
-25.61%
Free cash flow per share (TTM)
-0.871
Growth
Revenue change (TTM)
-51.65%
Earnings per share change (TTM)
-93.99%
3-year earnings per share growth (CAGR)
-69.59%
Bulls say / Bears say
The FDA agreed that X4 can reduce 4WARD enrollment from 176 to 126 patients while preserving adequate overall power for the co-primary endpoints, potentially lowering trial cost and execution risk; enrollment is now targeted for completion by year-end 2026. (SEC filing)
XOLREMDI gained European Commission approval as the first and only authorized WHIM-syndrome treatment in the EU, with Norgine handling commercialization and X4 eligible for up to €226 million in milestones plus escalating double-digit royalties. (X4 Pharmaceuticals)
The company had $195.1 million of cash and cash equivalents at June 30, 2026, and management said its balance sheet provides runway into 2029; U.S. XOLREMDI product sales also rose to $4.8 million in the first half from $2.7 million a year earlier. (SEC Form 10-Q)
4WARD remains a binary Phase 3 catalyst: topline data are not expected until the first half of 2028, and the FDA cautioned that its Type C feedback is nonbinding and that the smaller 126-patient sample could impair statistical significance. (SEC filing)
Commercial traction remains modest relative to the valuation risk: second-quarter 2026 U.S. XOLREMDI net product sales were $2.4 million, while most of the $8.8 million quarterly revenue came from a $6.4 million Norgine-related license milestone rather than recurring product sales. (SEC Form 10-Q)
X4 remains loss-making and cash-burning: it reported a $36.4 million net loss and $40.4 million of operating cash use in the first half of 2026, and its filing says product licensing and sales will not fund operating expenses over the next 12 months, creating eventual financing or dilution risk. (SEC Form 10-Q)
Data summarised monthly by Lightyear AI. Last updated on 8 Sept 2026.
Upcoming events
No upcoming events
Funds containing XFOR
Fund name | Fund size | $XFOR weighting |
|---|---|---|
SPDR Russell 2000 US Small Cap€R2US | €4.8B | 0.00% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.